Lung Cancer – Page 5 – Medical News Asia

AACR 2018: first-line atezolizumab, bevacizumab plus chemotherapy active in non-squamous NSCLC

10 May 2018/4 Comments/in Lung Cancer, Oncology, Chemotherapy, Immunotherapy, Translational Research/by Stijn van den Borne, MSc

First-line atezolizumab plus bevacizumab, carboplatin and paclitaxel improves PFS in patients with non-squamous NSCLC. Two presentations on the IMPower150 study by Martin Reck (ELCC 2018) and Mark Socinski (AACR 2018) discussed the frontline addition of atezolizumab to bevacizumab and chemotherapy in different lung cancer subgroups (NCT02366143).

Nivolumab-Ipilimumab Combination: A New Option for TMB-High NSCLC (CheckMate 227)

21 April 2018/6 Comments/in Lung Cancer, Oncology, Chemotherapy, Immunotherapy, Translational Research/by Stijn van den Borne, MSc

AACR 2018: First-line nivolumab-ipilimumab in TMB-high NSCLC with was associated with a more than tripled 1-year progression-free survival (PFS) rate compared to platinum-based chemotherapy in the Phase III CheckMate 227 trial (NCT02477826).

FDA approved osimertinib for the 1st-line treatment of patients with EGFR exon 19 deletions or exon 21 L858R mutations positive metastatic non-small cell lung cancer (NSCLC)

19 April 2018/0 Comments/in US FDA Onc\Haem Approvals, Lung Cancer, Oncology, Targeted Therapies, Translational Research/by scienterrific

edit+xClone Element

FDA approved osimertinib (Tagrisso, AstraZeneca Pharmaceuticals LP) for the 1st-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.

Frontline Combination of Pembrolizumab and Chemotherapy: A New Standard of Care for Non-squamous NSCLC

19 April 2018/4 Comments/in Lung Cancer, Oncology, Chemotherapy, Immunotherapy, Translational Research/by Stijn van den Borne, MSc

AACR 2018: Frontline pembrolizumab plus chemotherapy in NSCLC reduces the risk of death by more than 50%. The Phase III KEYNOTE-189 trial combined pembrolizumab (Keytruda®) plus standard of care platinum-based chemotherapy in non-squamous non–small cell lung cancer (NSCLC) without EGFR or ALK genetic aberrations (NCT0278680)

Pembrolizumab effective in frontline NSCLC with low PD-L1 expression

10 April 2018/1 Comment/in Lung Cancer, Oncology, Chemotherapy, Immunotherapy, Translational Research/by Stijn van den Borne, MSc

Pembrolizumab (Keytruda®) as single-agent immunotherapy in the frontline setting of any histology NSCLC with a PD-L1 expression ≥1% was associated with improved overall survival (OS) when compared to platinum-doublet chemotherapy in the KEYNOTE-042.

Crizotinib beneficial for East-Asian NSCLC patients with ROS1 alterations

4 April 2018/1 Comment/in China, Lung Cancer, Oncology, Targeted Therapies/by Stijn van den Borne, MSc

Crizotinib in Asian NSCLC patients with ROS1 alterations was associated with a 71.7% objective response rate (ORR) with a median duration of response (DOR) of 19.7 months (95% CI, 14.1 months – not reached). Learn more about the results with crizotinib in East-Asian non-small cell lung cancer (NSCLC) patients harbouring c-ros oncogene 1 (ROS1) rearrangements.

Making sense of 1st-line immunotherapy in non-small cell lung cancer (NSCLC)

26 March 2018/5 Comments/in Lung Cancer, Oncology, Immunotherapy, Guidelines/by Stijn van den Borne, MSc

The expansion of therapeutic options with immunotherapies will reflect a dramatic change in the guidelines for lung cancer, where immunotherapies mostly compete with the use of chemotherapeutic agents. A brief communication on immunotherapies for NSCLC.